Home > Insider Trading > Filing (0001209191-21-065041)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1746466	Equillium Inc.	EQ	Pharmaceutical Preparations (2834)	821554746

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1797818	Christine Zedelmayer	2223 Avenida De La Playa Suite 105 La Jolla CA 92037	Sr. Vice President And Coo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-11-16	8,334	$2.45	98,843	No	4	M	Direct
Common Stock	Disposition	2021-11-16	4,084	$5.49	94,759	No	4	S	Direct
Common Stock	Acquisiton	2021-11-16	15,000	$2.45	109,759	No	4	M	Direct
Common Stock	Disposition	2021-11-16	7,350	$5.49	102,409	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option	Disposition	2021-11-16	8,334	$0.00	8,334	$2.45
Common Stock	Employee Stock Option	Disposition	2021-11-16	15,000	$0.00	15,000	$2.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
41,666	2020-02-13	2029-02-12	No	4	M	Direct
75,000	2020-12-10	2029-12-09	No	4	M	Direct

Footnotes

The stock option exercises reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 17, 2021.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2021. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.40 to $5.59, inclusive. The reporting person undertakes to provide to Equillium, Inc., any security holder of Equillium, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
In accordance with Instruction 4 to this Form, Column 9 reports only total beneficial ownership of the "class" of derivative security reported in Column 1. Options that have different exercise prices or expiration dates are not considered to be of the same "class."